On May 1, 2026, Peng Lu, Chief Medical Officer of Pharvaris N.V. (PHVS), executed a scheduled sale of 14,166 shares for approximately $427,000, as disclosed in an SEC Form 4 filing. This transaction, conducted under a Rule 10b5-1 trading plan, indicates routine portfolio management rather than opportunistic trading, with Lu retaining significant equity exposure through 205,000 stock options.
For investors, Lu’s sale reflects a strategic move rather than a lack of confidence in Pharvaris, which is advancing therapies for hereditary angioedema (HAE). The company recently reported a slight increase in cash reserves and is on track to submit an application for its oral bradykinin receptor antagonist, deucrictibant, in the first half of 2026. However, it remains unprofitable, with substantial R&D expenses and a net loss of €176 million for 2025.
Investors should view Lu’s transaction as part of a planned strategy, while keeping an eye on Pharvaris’s upcoming clinical milestones, which could significantly impact its market position in the competitive HAE therapeutic landscape.
Source: fool.com